New pill could prevent liver failure in hepatitis b patients
NCT ID NCT07412236
First seen Feb 17, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This study tests a drug called hydronidone to see if it can stop or slow liver scarring (fibrosis) in people with chronic hepatitis B. About 1,200 adults aged 18-65 will take either hydronidone or a placebo, along with standard antiviral therapy, for up to 5 years. The goal is to prevent serious liver problems like cirrhosis, liver cancer, or need for a transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact
Conditions
Explore the condition pages connected to this study.